No way [Dissolution / BCS / IVIVC]

posted by Ohlbe – France, 2019-01-27 19:18 (1887 d 19:32 ago) – Posting: # 19813
Views: 2,452

Dear yuvaneshwari,

❝ Since API is in solution state filled in capsule, its solubility/bioavailability is improved tremendously.


❝ In the above scenario, can we consider for BCS based waiver approach ?


I think you have answered your own question. If solubility is the limiting factor, and your product has an improved solubility compared to the reference, how could you justify any kind of biowaiver ?

In any case: BCS-based biowaivers are only possible for class I and III products. Not the slightest chance if you're dealing with class II or IV.

Regards
Ohlbe

Complete thread:

UA Flag
Activity
 Admin contact
22,957 posts in 4,819 threads, 1,636 registered users;
110 visitors (0 registered, 110 guests [including 10 identified bots]).
Forum time: 14:51 CET (Europe/Vienna)

With four parameters I can fit an elephant,
and with five I can make him wiggle his trunk.    John von Neumann

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5